摘要
目的探讨细胞膜ＩＬ－２Ｒα链（ＣＤ２５）、ＮＫ细胞的Ｌｅｕ－１９抗原（ＣＤ５６）与恶性肿瘤的病情变化及治疗预后间的关系，并进一步探索ＣＤ２５与ＣＤ５６间的相互关系。方法用流式细胞术测定１６５例恶性肿瘤病人的ＣＤ２５、ＣＤ５６的结合表达率。结果在恶性肿瘤病人转移与非转移间及化疗前后均有明显变化（Ｐ＜０．０１）。且ＣＤ２５与ＣＤ５６均显示有明显的负相关。结论动态观察恶性肿瘤病人ＣＤ２５、ＣＤ５６，可提示其预后及机体抗肿瘤能力。
Objectives To explore the relationship between the mIL-2R (CD25)Leu-19 antigen (CD56) of the natural killer cell and the change of disease condition, prognosis of the treatment in malignant tumor. Methods The expression rates of the CD25CD56 in 165 malignant tumor patients were examined by using flow cytometry. Results The expression rate of CD25 in prechemotherapy was significantly lower than that of postchemotherapy (P<0.05). The expression rate of CD56 in prechmotherapy was significantly higher than that of postchemotherapy (P<0.05). The expression rate of CD56 in nonmetastatic group was significantly lower than that of metastatic group (P<0.05). The expression rate of CD25 in no metastatic was significantly higher than that of metastatic group (P<0.01). A negative correlation presented between the CD25 and CD56. Conclusions It might be helpful of testing CD25CD56 for stage judgement and prognosis evaluation in malignant tumor.
出处
《中国肿瘤临床与康复》
1999年第2期31-32,共2页
Chinese Journal of Clinical Oncology and Rehabilitation
